Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug
Fuente:
FierceBiotech
Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at 42 weeks in a phase 2 obesity trial.